Marksans Pharma Ltd. (NSE: MARKSANS) and Pfizer Ltd. (NSE: PFIZER) are both listed in the Pharmaceuticals industry. Marksans Pharma has a market capitalisation of ₹14,152 Cr and Pfizer ₹16,646 Cr, as of 9 Nov 2026. Their P/E ratios are 33.9 and 23 respectively. Return on equity is 25.45% for Marksans Pharma and 17.16% for Pfizer. Over one year, Marksans Pharma's share price is up 62.3% and Pfizer's is down 24.3%.
| Metric | Marksans Pharma | Pfizer |
|---|---|---|
| NSE Symbol | MARKSANS | PFIZER |
| BSE Code | 524404 | 500680 |
| Share Price | ₹309.00 | ₹3,923.50 |
| Market Cap | ₹14,152 Cr | ₹16,646 Cr |
| P/E Ratio | 33.9 | 23 |
| Return on Equity | 25.45% | 17.16% |
| Return on Assets | 8.85% | 10.77% |
| Dividend Yield | 0.29% | 2.06% |
| Beta (1Y) | 0.7 | 0.34 |
| 1-Year Price Change | +62.3% | -24.3% |
| 3-Month Price Change | +13.8% | -19.6% |
| 52-Week Range | ₹155.00 – ₹350.95 | ₹3,589.00 – ₹5,339.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹940 Cr | ₹727 Cr |
| Quarterly Net Profit | ₹144 Cr | ₹313 Cr |
| Net Margin | 15.3% | 43.1% |
| EPS (Basic, Quarter) | ₹3.12 | ₹68.47 |
| Results Basis | consolidated | standalone |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeuti…
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was…
Pfizer has a market capitalisation of ₹16,646 Cr, against ₹14,152 Cr for Marksans Pharma as of 9 Nov 2026, about 1.2 times the size by market cap.
Marksans Pharma has a P/E of 33.9 and Pfizer a P/E of 23 as of 9 Nov 2026.
Marksans Pharma has a return on equity of 25.45% and Pfizer 17.16%.
Marksans Pharma's share price is up 62.3% over one year and Pfizer's is down 24.3%.
Marksans Pharma reported revenue of ₹940 Cr and net profit of ₹144 Cr for Q2 FY27. Pfizer reported revenue of ₹727 Cr and net profit of ₹313 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.